TESARO Inc (TSRO) was Upgraded by BofA/Merrill to ” Buy”. Earlier the firm had a rating of “Neutral ” on the company shares. BofA/Merrill advised their investors in a research report released on Oct 10, 2016.
Many Wall Street Analysts have commented on TESARO Inc. Company shares were Reiterated by RBC Capital Mkts on Oct 10, 2016 to “Outperform”, Firm has raised the Price Target to $ 128 from a previous price target of $122 .Company shares were Reiterated by Wedbush on Oct 10, 2016 to “Outperform”, Firm has raised the Price Target to $ 139 from a previous price target of $107 .Company shares were Reiterated by FBR & Co. on Oct 10, 2016 to “Outperform”, Firm has raised the Price Target to $ 115 from a previous price target of $102 .
On the company’s financial health, TESARO Inc reported $-1.28 EPS for the quarter, beating the analyst consensus estimate by $ 0.42 according to the earnings call on Aug 4, 2016. Analyst had a consensus of $-1.70. The company had revenue of $36.60 million for the quarter, compared to analysts expectations of $2.48 million. During the same quarter in the previous year, the company posted $-1.51 EPS.
TESARO Inc closed down -0.63 points or -0.63% at $99.26 with 13,64,709 shares getting traded on Friday. Post opening the session at $100.21, the shares hit an intraday low of $96.52 and an intraday high of $101.6 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
In a different news, on Sep 23, 2016, Martin H. Jr. Huber (SVP & Chief Medical Officer) sold 408 shares at $108.12 per share price. According to the SEC, on Sep 9, 2016, Edward C English (V.P.Finance and Administration) sold 7,000 shares at $89.15 per share price. On Sep 1, 2016, Jeffrey H. Hanke (Executive VP, R&D and CSO) sold 29,166 shares at $86.04 per share price, according to the Form-4 filing with the securities and exchange commission.
TESARO Inc. (TESARO) is oncology-focused biopharmaceutical company. The Company acquires in-licenses and develops oncology product candidates. The Company has in-licensed and are developing three clinical-stage product candidates rolapitant niraparib and TSR-011. Rolapitant is a potent and long-acting neurokinin-1 or NK-1 receptor antagonist for the prevention of chemotherapy induced nausea and vomiting (CINV); Niraparib formerly known as MK-4827 is an orally active and potent poly (ADP-ribose) polymerase and TSR-011 is an orally available targeted anti-cancer agent which is a potent inhibitor of both anaplastic lymphoma kinase (ALK) and tropomyosin-related kinase (TRK). The Company is also developing immuno-oncology programs by entering into a collaboration and exclusive license agreement with AnaptysBio Inc. for the discovery and development of antibodies for several specified immuno-oncology targets.